Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

British Journal of Haematology
P FenauxCharles L Beach

Abstract

In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) who are ineligible for intensive treatment, was found to be associated with poorer survival compared with azacitidine. This analysis further compared the efficacy and the toxicity of these two drug regimens. Before randomization, investigators preselected patients to receive a conventional care regimen, one of which was LDara-C. Of 94 patients preselected to LDara-C, 45 were randomized to azacitidine and 49 to LDara-C. Azacitidine patients had significantly more and longer haematological responses and increased red blood cell transfusion independence. Azacitidine prolonged overall survival versus LDara-C in patients with poor cytogenetic risk, presence of -7/del(7q), and French-American-British subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. When analyzed per patient year of drug exposure, azacitidine treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk MDS patients.

References

May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
Sep 6, 2002·Seminars in Hematology·Razelle Kurzrock
Jan 25, 2003·British Journal of Haematology·David BowenUNKNOWN UK MDS Guidelines Group
Sep 17, 2004·Leukemia & Lymphoma·Giuseppe VisaniAlessandro Isidori
Jan 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin R WeiserW Douglas Wong

❮ Previous
Next ❯

Citations

Oct 17, 2012·Annals of Hematology·Sho HangaiMineo Kurokawa
Jan 18, 2012·Current Opinion in Hematology·Raphael Itzykson, Pierre Fenaux
Jun 27, 2012·Haematologica·Andréa TomaCatherine Cordonnier
Dec 21, 2013·International Journal of Clinical Oncology·Takayuki Ishikawa
Aug 21, 2013·Blood Reviews·Amer M ZeidanSteven D Gore
May 23, 2013·Blood·Margaret A Goodell, Lucy A Godley
Oct 28, 2015·Genes·Constantin F PixbergRui P L Neves
Oct 11, 2011·Advances in Biological Regulation·Matilde Y FolloLucio Cocco
Sep 25, 2014·American Journal of Hematology·Naveen PemmarajuFarhad Ravandi
Sep 18, 2010·Trends in Pharmacological Sciences·Xiaojing YangPeter A Jones
Nov 26, 2011·Vox Sanguinis·S D RamseyH Joachim Deeg
May 11, 2012·British Journal of Haematology·Shanti Natarajan-AméUNKNOWN Groupe Francophone des Myélodysplasies (GFM)
Mar 31, 2016·International Journal of Molecular Sciences·Harinder GillYok-Lam Kwong
Aug 20, 2014·British Journal of Pharmacology·David CheishviliMoshe Szyf
Apr 23, 2015·Vox Sanguinis·E TsengR Buckstein
Jul 6, 2015·Current Treatment Options in Oncology·Simon B Zeichner, Martha L Arellano
Mar 25, 2014·Lancet·Lionel AdèsPierre Fenaux
Oct 30, 2012·La Revue de médecine interne·O Beyne-Rauzy
Jun 10, 2010·Clinical Journal of Oncology Nursing·Sandra E Kurtin, Erin P Demakos
Dec 8, 2015·Hematology·Mark A Schroeder, Amy E DeZern
Oct 27, 2017·Expert Review of Hematology·Roberto CastelliGiorgio Lambertenghi-Deliliers
Nov 7, 2013·Expert Review of Hematology·Drorit G Merkel, Arnon Nagler
Jan 13, 2015·Expert Review of Hematology·David J Seastone, Aaron T Gerds
Dec 7, 2019·Hematology·Guillermo F Sanz
Jan 9, 2020·British Journal of Clinical Pharmacology·Justine PerinoSophie Dimicoli-Salazar
Aug 9, 2011·Bulletin du cancer·Raphael Itzykson, Pierre Fenaux

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.